Amarin Corp Plcuk (AMRN) Share-based Compensation (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Share-based Compensation of $2.3 million for Q1 2026, down 46.13% year-over-year from $4.3 million in Q1 2025, and up 44.33% quarter-over-quarter from $1.6 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Share-based Compensation (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Share-based Compensation data on file, last reported at $2.3 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $2.3 million, down 46.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.9 million (down 28.98% YoY), and the FY2025 annual result was $13.9 million, down 21.28% from the prior year.
- Share-based Compensation improved to $2.3 million in Q1 2026 per AMRN's latest filing, from $1.6 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $8.6 million in Q2 2022 and troughed at $1.6 million in Q4 2025.
- A 5-year average of $4.5 million and a median of $4.6 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 248.77% in 2022, then tumbled 78.78% in 2023.
- A 5-year view of Share-based Compensation shows it stood at $6.6 million in 2022, then declined by 29.72% to $4.6 million in 2023, then dropped by 26.79% to $3.4 million in 2024, then slumped by 52.53% to $1.6 million in 2025, then surged by 44.33% to $2.3 million in 2026.
- Business Quant data shows AMRN's Share-based Compensation at $2.3 million in Q1 2026, $1.6 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 161.00 Mn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 300.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 444.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 185.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 218.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 272.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 146.00 Mn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | 2.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.33 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Sep 30, 2025 | 1.96 Mn |
| Sep 30, 2025 | 1.96 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Mar 31, 2025 | 4.33 Mn |
| Mar 31, 2025 | 4.33 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Sep 30, 2024 | 4.70 Mn |
| Sep 30, 2024 | 4.70 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 5.22 Mn |
| Mar 31, 2024 | 5.22 Mn |
| Dec 31, 2023 | 4.65 Mn |
| Dec 31, 2023 | 4.65 Mn |